NCT07431840

Brief Summary

The primary goal of this study is to observe the impact of the IDP® Supplement on the duration and severity of upper respiratory symptoms in older individuals during the cold and flu season. Secondary aims include observing the product's effect on rescue medication use, quality of life, and overall tolerability. This is conducted as a consumer-driven, decentralized observational clinical research study in adults aged 60 or older, using self-reported measures and questionnaires completed at home via the Chloe App.

Trial Health

77
On Track

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Enrollment
300

participants targeted

Target at P75+ for not_applicable

Timeline
3mo left

Started Dec 2025

Shorter than P25 for not_applicable

Geographic Reach
1 country

1 active site

Status
recruiting

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

Study Progress65%
Dec 2025Jul 2026

Study Start

First participant enrolled

December 5, 2025

Completed
3 months until next milestone

First Submitted

Initial submission to the registry

February 19, 2026

Completed
6 days until next milestone

First Posted

Study publicly available on registry

February 25, 2026

Completed
3 months until next milestone

Primary Completion

Last participant's last visit for primary outcome

May 19, 2026

Expected
2 months until next milestone

Study Completion

Last participant's last visit for all outcomes

July 31, 2026

Last Updated

March 12, 2026

Status Verified

February 1, 2026

Enrollment Period

6 months

First QC Date

February 19, 2026

Last Update Submit

March 10, 2026

Conditions

Upper Respiratory DiseaseInfluenzaViral Upper Respiratory Infection

Keywords

ColdFluViral Upper Respiratory InfectionURIInfluenzaLungsUpper Respiratory TractUpper RespiratoryPneumonia

Outcome Measures

Primary Outcomes (1)

  • Impact on Upper Respiratory Symptom Incidence, Duration and Severity

    To evaluate the impact of IDP® Preventative Supplementation on incidence of upper respiratory symptoms, and the duration and severity of any symptoms that occur by measuring the change in incidence of upper respiratory symptoms (frequency, type, duration and severity) between study product and placebo groups. Baseline will be compared as well.

    17 weeks

Secondary Outcomes (4)

  • Impact of IDP on Upper Respiratory Symptoms

    17 weeks

  • Impact on Rescue Medications

    17 weeks

  • Impact on Quality of Life

    17 weeks

  • Safety and Tolerability Assessment

    16 weeks

Study Arms (3)

Group 1: Study Product 50mg Dose

EXPERIMENTAL

50mg of Study Product

Dietary Supplement: Immune Defense Protein 50mg Dose

Group 2: Study Product 200mg Dose

EXPERIMENTAL

200mg of Study Product

Dietary Supplement: IDP 200mg Dose

Group 3: Matching Placebo

PLACEBO COMPARATOR

Participants will receive Matching Placebo

Dietary Supplement: Matching Placebo

Interventions

Immune Defense Protein 50mg DoseDIETARY_SUPPLEMENT

IDP dose of 50mg

Group 1: Study Product 50mg Dose
IDP 200mg DoseDIETARY_SUPPLEMENT

IDP dose of 200mg

Group 2: Study Product 200mg Dose
Matching PlaceboDIETARY_SUPPLEMENT

Matching Placebo

Group 3: Matching Placebo

Eligibility Criteria

Age60 Years+
Sexall
Healthy VolunteersYes
Age GroupsAdult (18-64), Older Adult (65+)

You may qualify if:

  • Age 60 years and older
  • Individuals who experience upper respiratory symptoms (e.g. coughing, sneezing, congestion) at least 2-3 times during the cold/flu season.
  • Able to read and understand English.
  • Able to read, understand, and provide informed consent.
  • Able to use a personal smartphone device and download Chloe by People Science.
  • Able to receive shipment of the product at an address within the United States.

You may not qualify if:

  • Any potential participants who:
  • Do not have a personal smartphone, internet access, or unwilling to download Chloe.
  • Already in an immunocompromised state, including:
  • A. Infectious Causes
  • HIV/AIDS
  • Chronic hepatitis B or C (advanced stages)
  • Tuberculosis (especially disseminated or extrapulmonary TB) B. Cancer-Related
  • Leukemia (e.g., AML, ALL, CLL)
  • Lymphoma (e.g., Hodgkin's and Non-Hodgkin's)
  • Multiple Myeloma
  • Any metastatic cancer receiving chemotherapy
  • C. Immunosuppressive Therapy:
  • Participants on:
  • Corticosteroids (e.g., ≥20 mg/day of prednisone for ≥2 weeks)
  • Biologics (e.g., TNF inhibitors like infliximab, adalimumab)
  • +22 more criteria

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Study Sites (1)

People Science, Inc.

Los Angeles, California, 90045, United States

RECRUITING

MeSH Terms

Conditions

Respiration DisordersInfluenza, HumanCommon ColdPneumonia

Interventions

Inosine Diphosphate

Condition Hierarchy (Ancestors)

Respiratory Tract DiseasesRespiratory Tract InfectionsInfectionsOrthomyxoviridae InfectionsRNA Virus InfectionsVirus DiseasesPicornaviridae InfectionsLung Diseases

Intervention Hierarchy (Ancestors)

Inosine NucleotidesPurine NucleotidesPurinesHeterocyclic Compounds, 2-RingHeterocyclic Compounds, Fused-RingHeterocyclic CompoundsNucleotidesNucleic Acids, Nucleotides, and NucleosidesRibonucleotides

Central Study Contacts

Noah Craft, M.D., Ph.D

CONTACT

213-328-0919noah@peoplescience.health

Azure Grant

CONTACT

azure@peoplescience.health

Study Design

Study Type
interventional
Phase
not applicable
Allocation
RANDOMIZED
Masking
DOUBLE
Who Masked
PARTICIPANT, INVESTIGATOR
Purpose
SUPPORTIVE CARE
Intervention Model
PARALLEL
Sponsor Type
INDUSTRY
Responsible Party
SPONSOR

Study Record Dates

First Submitted

February 19, 2026

First Posted

February 25, 2026

Study Start

December 5, 2025

Primary Completion (Estimated)

May 19, 2026

Study Completion (Estimated)

July 31, 2026

Last Updated

March 12, 2026

Record last verified: 2026-02

Locations

US(1)